John W. Longshore

John Longshore is the Head of Scientific Affairs for Global Oncology Diagnostics at AstraZeneca. The Scientific Affairs team is accountable for the development and execution of global scientific strategy for AstraZeneca oncology diagnostic solutions worldwide. This includes maximizing global biomarker adoption, facilitating the development of local testing solutions, generating analytical performance data, and leading medical education for the laboratory community.

He works across the organization, often with colleagues in Global Diagnostics, Medical Affairs, Policy, and local in-market teams to support the identification of key gaps and solutions for improved access to biomarker testing. John currently serves as the Chair of the Precision Cancer Consortium, a group of like-minded pharmaceutical companies who collaborate to address biomarker testing challenges. For both AstraZeneca and the PCC, the goal is to ensure that all patients have access to high-quality and timely biomarker testing.

Prior to joining AstraZeneca, John served for 20 years as the Director of Molecular Pathology for Carolinas Pathology Group. His job included being the Medical Director for the Molecular Pathology Laboratory for Atrium Health, a comprehensive molecular laboratory providing services to a large integrated care network. During this time, his laboratory has served as central pathology for multiple clinical trials that have led to the FDA approval of companion diagnostic assays, for both tissue and ctDNA. His laboratory was recognized as a global center of excellence for biomarker profiling in oncology, personalized medicine, and biomarker education.

Dr. Longshore is a diplomate of the American Board of Medical Genetics and Genomics and is an active member of multiple global professional societies. His focal area of academic interest is the use of molecular markers in oncology to enable patient access to targeted therapies.